{"protocolSection": {"identificationModule": {"nctId": "NCT00391846", "orgStudyIdInfo": {"id": "D2452L00010"}, "secondaryIdInfos": [{"id": "EUDRACT No. 2006-001259-36"}, {"id": "SIGNAL HF"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone", "officialTitle": "A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Systolic Dysfunction"}, "statusModule": {"statusVerifiedDate": "2012-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-10"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-10-19", "studyFirstSubmitQcDate": "2006-10-23", "studyFirstPostDateStruct": {"date": "2006-10-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-10", "resultsFirstSubmitQcDate": "2012-05-15", "resultsFirstPostDateStruct": {"date": "2012-06-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-06-18", "lastUpdatePostDateStruct": {"date": "2012-06-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction"}, "conditionsModule": {"conditions": ["Heart Failure", "Ventricular Dysfunction, Left"], "keywords": ["Heart Failure", "Ventricular Dysfunction", "NTproBNP"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 252, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Guided by NT-proBNP", "type": "OTHER", "description": "Treatment guided by clinical symptoms and signs + NTproBNP", "interventionNames": ["Drug: Captopril", "Drug: Enalapril", "Drug: Lisinopril", "Drug: Ramipril", "Drug: Trandolapril", "Drug: Bisoprolol", "Drug: Carvedilol", "Drug: Metoprolol succinate", "Drug: Candesartan", "Drug: Valsartan", "Drug: Eplerenone", "Drug: Spironolactone", "Drug: Diuretics", "Drug: HF treatment according to Swedish guidelines", "Procedure: Blood samples", "Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)"]}, {"label": "Not Guided by NT-proBNP", "type": "OTHER", "description": "Treatment guided by clinical symptoms and signs", "interventionNames": ["Drug: Captopril", "Drug: Enalapril", "Drug: Lisinopril", "Drug: Ramipril", "Drug: Trandolapril", "Drug: Bisoprolol", "Drug: Carvedilol", "Drug: Metoprolol succinate", "Drug: Candesartan", "Drug: Valsartan", "Drug: Eplerenone", "Drug: Spironolactone", "Drug: Diuretics", "Drug: HF treatment according to Swedish guidelines", "Procedure: Blood samples", "Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)"]}], "interventions": [{"type": "DRUG", "name": "Captopril", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Enalapril", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Lisinopril", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Ramipril", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Trandolapril", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Bisoprolol", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Carvedilol", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Metoprolol succinate", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Candesartan", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"], "otherNames": ["Atacand"]}, {"type": "DRUG", "name": "Valsartan", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Eplerenone", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Spironolactone", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "Diuretics", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "DRUG", "name": "HF treatment according to Swedish guidelines", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "PROCEDURE", "name": "Blood samples", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}, {"type": "PROCEDURE", "name": "The Kansas City Cardiomyopathy Questionnaire (KCCQ)", "armGroupLabels": ["Guided by NT-proBNP", "Not Guided by NT-proBNP"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)", "description": "The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented", "timeFrame": "9 months"}], "secondaryOutcomes": [{"measure": "Number of CV Deaths", "description": "Number of deaths", "timeFrame": "9 months"}, {"measure": "Number of Days in Hospital for CV Reason", "description": "Each overnight stay is counted as one day. The lower the better", "timeFrame": "9 months"}, {"measure": "Changes in Heart Failure Symptoms", "description": "Changes from baseline in the symptom score subset (question 3, 5, 7 and 9) of KCCQ (swelling, fatigue, shortness of breath, shortness of breath night time). KCCQ is a self-administered by patient symptom score, where higher score reflect better health status. Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. This mean that the KCCQ scale is from 0 to 100 with the higher value showing a better health status.", "timeFrame": "9 months and baseline"}, {"measure": "Changes in NT-proBNP Values Over Time in All Patients", "description": "The 95% confidential interval (CI) is given as measure of dispersion", "timeFrame": "9 months and baseline"}, {"measure": "Changes in Health-related Quality of Life", "description": "Change range -100 to 100. The higher the better.", "timeFrame": "9 months and baseline"}, {"measure": "Total Number of Titration Steps in Prescribed Heart Failure Treatment", "description": "Each titration step in prescribed medication is counted as one step, either up or down. One step up indicates an increase of dose in prescribed medication and one step down indicates a decrease of dose in prescribed medication. The sum of steps is given as a score. Score is given for each arm as a total number of titration steps for all patients in arm.", "timeFrame": "9 months"}, {"measure": "Discontinuations", "description": "Number of patients discontinued due to adverse events'", "timeFrame": "9 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female/male, over 18 years with previously verified HF with left ventricular systolic dysfunction.\n* New York Heart Association(NYHA) class II-IV,\n* NTproBNP males\\>800 ng/L, females \\>1000 ng/L\n\nExclusion Criteria:\n\n* Planned CV hospitalisation, stroke or acute myocardial infarction (MI) last 3 months,\n* Mitral/aortic stenosis,\n* Patients already receiving optimal HF treatment,\n* Severe reduction of kidney function", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AstraZeneca Sweden Medical Director, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}, {"name": "Hans Persson, MD, PhD", "affiliation": "Danderyd Hospital, Sweden", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Bjorn Eriksson, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Alvesta", "country": "Sweden", "geoPoint": {"lat": 56.89935, "lon": 14.55559}}, {"facility": "Research Site", "city": "Arvika", "country": "Sweden", "geoPoint": {"lat": 59.65528, "lon": 12.58518}}, {"facility": "Research Site", "city": "Bjuv", "country": "Sweden", "geoPoint": {"lat": 56.08372, "lon": 12.91914}}, {"facility": "Research Site", "city": "Borensberg", "country": "Sweden", "geoPoint": {"lat": 58.56667, "lon": 15.28333}}, {"facility": "Research Site", "city": "Bromma", "country": "Sweden", "geoPoint": {"lat": 59.34, "lon": 17.94}}, {"facility": "Research Site", "city": "Dalby", "country": "Sweden", "geoPoint": {"lat": 55.66655, "lon": 13.34976}}, {"facility": "Research Site", "city": "Eskilstuna", "country": "Sweden", "geoPoint": {"lat": 59.36661, "lon": 16.5077}}, {"facility": "Research Site", "city": "Gagnef", "country": "Sweden", "geoPoint": {"lat": 60.59856, "lon": 15.07745}}, {"facility": "Research Site", "city": "Goeteborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Hisings Karra", "country": "Sweden"}, {"facility": "Research Site", "city": "Huddinge", "country": "Sweden", "geoPoint": {"lat": 59.23705, "lon": 17.98192}}, {"facility": "Research Site", "city": "Huskvarna", "country": "Sweden", "geoPoint": {"lat": 57.78596, "lon": 14.30214}}, {"facility": "Research Site", "city": "Joenkoeping", "country": "Sweden"}, {"facility": "Research Site", "city": "Kalmar", "country": "Sweden", "geoPoint": {"lat": 56.66157, "lon": 16.36163}}, {"facility": "Research Site", "city": "Kungalv", "country": "Sweden", "geoPoint": {"lat": 57.87096, "lon": 11.98054}}, {"facility": "Research Site", "city": "Lerum", "country": "Sweden", "geoPoint": {"lat": 57.77051, "lon": 12.26904}}, {"facility": "Research Site", "city": "Lessebo", "country": "Sweden", "geoPoint": {"lat": 56.75185, "lon": 15.26969}}, {"facility": "Research Site", "city": "Lidkoping", "country": "Sweden", "geoPoint": {"lat": 58.50517, "lon": 13.15765}}, {"facility": "Research Site", "city": "Lilla Edet", "country": "Sweden", "geoPoint": {"lat": 58.13333, "lon": 12.13333}}, {"facility": "Research Site", "city": "Linkoeping", "country": "Sweden"}, {"facility": "Research Site", "city": "Ludvika", "country": "Sweden", "geoPoint": {"lat": 60.14959, "lon": 15.18776}}, {"facility": "Research Site", "city": "Lyckeby", "country": "Sweden", "geoPoint": {"lat": 56.2, "lon": 15.65}}, {"facility": "Research Site", "city": "Malmo", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "Research Site", "city": "Moheda", "country": "Sweden", "geoPoint": {"lat": 57.0, "lon": 14.56667}}, {"facility": "Research Site", "city": "Motala", "country": "Sweden", "geoPoint": {"lat": 58.53706, "lon": 15.03649}}, {"facility": "Research Site", "city": "Orebro", "country": "Sweden", "geoPoint": {"lat": 59.27412, "lon": 15.2066}}, {"facility": "Research Site", "city": "Ostersund", "country": "Sweden", "geoPoint": {"lat": 63.1792, "lon": 14.63566}}, {"facility": "Research Site", "city": "Skanor", "country": "Sweden", "geoPoint": {"lat": 55.41667, "lon": 12.85}}, {"facility": "Research Site", "city": "Soderakra", "country": "Sweden", "geoPoint": {"lat": 56.45, "lon": 16.06667}}, {"facility": "Research Site", "city": "Stenungsund", "country": "Sweden", "geoPoint": {"lat": 58.07046, "lon": 11.8181}}, {"facility": "Research Site", "city": "Stocksund", "country": "Sweden", "geoPoint": {"lat": 59.38333, "lon": 18.06667}}, {"facility": "Research Site", "city": "Timra", "country": "Sweden", "geoPoint": {"lat": 62.48654, "lon": 17.32613}}, {"facility": "Research Site", "city": "Uddevalla", "country": "Sweden", "geoPoint": {"lat": 58.34784, "lon": 11.9424}}, {"facility": "Research Site", "city": "Ulricehamn", "country": "Sweden", "geoPoint": {"lat": 57.79159, "lon": 13.41422}}, {"facility": "Research Site", "city": "Umea", "country": "Sweden", "geoPoint": {"lat": 63.82842, "lon": 20.25972}}, {"facility": "Research Site", "city": "Uppsala", "country": "Sweden", "geoPoint": {"lat": 59.85882, "lon": 17.63889}}, {"facility": "Research Site", "city": "Vasteras", "country": "Sweden", "geoPoint": {"lat": 59.61617, "lon": 16.55276}}, {"facility": "Research Site", "city": "Vastervik", "country": "Sweden", "geoPoint": {"lat": 57.7584, "lon": 16.63733}}, {"facility": "Research Site", "city": "Vaxjo", "country": "Sweden", "geoPoint": {"lat": 56.87767, "lon": 14.80906}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "At visit 1 was the NT-proBNP value measured at this value should be above 800 (females) or 1000 (males) before randomisation at visit 2. One patient from each group are excluded from the full analysis set (FAS) due to \"total unavailability of efficacy data after randomisation\".", "recruitmentDetails": "This was a randomised, parallel group, single blind, multicentre, 9-month study in chronic heart failure in patients with New York Heart Association classification of heart failure (NYHA) class II-IV, left ventricular systolic dysfunction and elevated NT-proBNP levels in the primary care setting.", "groups": [{"id": "FG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "FG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Of the 127 randomised patients 8 were discontinued", "numSubjects": "127"}, {"groupId": "FG001", "comment": "Of th 125 randomised patients 7 were discontinued", "numSubjects": "125"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "119 completed patients includes 4 CV related deaths", "numSubjects": "119"}, {"groupId": "FG001", "comment": "118 completed patients includes 5 CV related deaths", "numSubjects": "118"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Did not meet the required elig. crit", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Developed study specific DC criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "BG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "252"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78", "lowerLimit": "57", "upperLimit": "92"}, {"groupId": "BG001", "value": "77", "lowerLimit": "51", "upperLimit": "94"}, {"groupId": "BG002", "value": "77", "lowerLimit": "51", "upperLimit": "94"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "72"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "97"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "180"}]}]}]}, {"title": "Electrocardiogram (ECG), Abnormal/Normal", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Abnormal ECG", "categories": [{"measurements": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "228"}]}]}, {"title": "Normal ECG", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "24"}]}]}]}, {"title": "Diastolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "73", "spread": "11"}, {"groupId": "BG001", "value": "75", "spread": "12"}, {"groupId": "BG002", "value": "74", "spread": "11"}]}]}]}, {"title": "Pulse", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Beats/minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71", "spread": "14"}, {"groupId": "BG001", "value": "72", "spread": "14"}, {"groupId": "BG002", "value": "72", "spread": "14"}]}]}]}, {"title": "Systolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "133", "spread": "21"}, {"groupId": "BG001", "value": "135", "spread": "22"}, {"groupId": "BG002", "value": "134", "spread": "21"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)", "description": "The non-parametric scale is constructed from 3 variables, modified after Cleland. Each patient receives a rank score from 1 to 246 (246-number of patients in the study). The lowest score receive patients who die (due to CV event), next patients still alive at end-of-study with the worst composite score, the best alive patients with 0 days in hospital and the largest improvement in the KCCQ (self-administered by patient symptom score, where the higher score reflect better health status). Scores will be summarized using non-parametric calculations. The mean of non-parametric scores is presented", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "9 months", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "118.6", "spread": "558"}, {"groupId": "OG001", "value": "128.4", "spread": "558"}]}]}]}, {"type": "SECONDARY", "title": "Number of CV Deaths", "description": "Number of deaths", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "9 months", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Number of Days in Hospital for CV Reason", "description": "Each overnight stay is counted as one day. The lower the better", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days in hospital", "timeFrame": "9 months", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.79", "spread": "6.63"}, {"groupId": "OG001", "value": "5.94", "spread": "6.32"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Heart Failure Symptoms", "description": "Changes from baseline in the symptom score subset (question 3, 5, 7 and 9) of KCCQ (swelling, fatigue, shortness of breath, shortness of breath night time). KCCQ is a self-administered by patient symptom score, where higher score reflect better health status. Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100. This mean that the KCCQ scale is from 0 to 100 with the higher value showing a better health status.", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Categorial scale", "timeFrame": "9 months and baseline", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.67", "spread": "20.02"}, {"groupId": "OG001", "value": "6.11", "spread": "21.00"}]}]}]}, {"type": "SECONDARY", "title": "Changes in NT-proBNP Values Over Time in All Patients", "description": "The 95% confidential interval (CI) is given as measure of dispersion", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/L", "timeFrame": "9 months and baseline", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2332.1", "lowerLimit": "1986.1", "upperLimit": "2738.4"}, {"groupId": "OG001", "value": "2063", "lowerLimit": "1743.2", "upperLimit": "2442.7"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Health-related Quality of Life", "description": "Change range -100 to 100. The higher the better.", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "KCCQ overall score", "timeFrame": "9 months and baseline", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.739", "spread": "1.39"}, {"groupId": "OG001", "value": "3.172", "spread": "1.39"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Titration Steps in Prescribed Heart Failure Treatment", "description": "Each titration step in prescribed medication is counted as one step, either up or down. One step up indicates an increase of dose in prescribed medication and one step down indicates a decrease of dose in prescribed medication. The sum of steps is given as a score. Score is given for each arm as a total number of titration steps for all patients in arm.", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Titration steps", "timeFrame": "9 months", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "517"}, {"groupId": "OG001", "value": "485"}]}]}]}, {"type": "SECONDARY", "title": "Discontinuations", "description": "Number of patients discontinued due to adverse events'", "populationDescription": "In the above analysis regarding The number of participants analyzed the 'last observation carried forward' principle is used, as pre-specified in the protocol.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "9 months", "groups": [{"id": "OG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP"}, {"id": "OG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "Only Serious Adverse Event were to be reported. Other Adverse Events (Non-Serious Adverse Events) were to be reported by investigators directly to MPA (Medical Product Agency) in accordance to local legislation.", "eventGroups": [{"id": "EG000", "title": "Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms, signs and NT-proBNP", "seriousNumAffected": 46, "seriousNumAtRisk": 127, "otherNumAffected": 0, "otherNumAtRisk": 127}, {"id": "EG001", "title": "Not Guided by NT-proBNP", "description": "Chronic heart failure treatment guided by clinical symptoms and signs", "seriousNumAffected": 41, "seriousNumAtRisk": 125, "otherNumAffected": 0, "otherNumAtRisk": 125}], "seriousEvents": [{"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Aortic Aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Aortic Stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Artial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 125}]}, {"term": "Atrioventricular Block Complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "B-Cell Lymphoma", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Bladder Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Bleeding Varicose Vein", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Blood Electrolytes Abnormal", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Blood Pressure Decreased", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Calculus Ureathral", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Cardiac Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 125}]}, {"term": "Carotid Artery Stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Cerebral Infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Chronic Lymphocytic Leukaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Chronic Obstructive Pulmonary Disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Confusional State", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Duodenal Ulcer Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Endocarditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Femur Fracture", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Gastrointestinal Tract Adenoma", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Haematemesis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Headache", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Heamorrhage", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Hepatic Failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Hip Fracture", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Intermittent Claudication", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Intervertebral Disc Compression", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Intestinal Ischaemia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Lung Neoplasm Malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Malnutrition", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Multi-Organ Failure", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Muscular Weakness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 125}]}, {"term": "Odema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Osteoporotic Fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Peripheral Embolism", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Peripheral Ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 125}]}, {"term": "Polymyalgia Rheumatica", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Pulmonary Odema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Pyelonephritis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Renal Failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 125}]}, {"term": "Respiratory Tract Infection Viral", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Rib Fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Right Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Septic Shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Sick Sinus Syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Spinal Column Stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Spinal Fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 125}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Therapeutic Agent Toxicity", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Urosepis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Venous Thrombosis Limb", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Ventricular Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Vertigo", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}, {"term": "Herpes Zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 125}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000018754", "term": "Ventricular Dysfunction"}, {"id": "D000018487", "term": "Ventricular Dysfunction, Left"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M20824", "name": "Ventricular Dysfunction", "asFound": "Ventricular Dysfunction", "relevance": "HIGH"}, {"id": "M20591", "name": "Ventricular Dysfunction, Left", "asFound": "Ventricular Dysfunction, Left", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008790", "term": "Metoprolol"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000077261", "term": "Carvedilol"}, {"id": "C000081643", "term": "Candesartan"}, {"id": "D000017257", "term": "Ramipril"}, {"id": "D000004656", "term": "Enalapril"}, {"id": "D000017706", "term": "Lisinopril"}, {"id": "D000077545", "term": "Eplerenone"}, {"id": "D000017298", "term": "Bisoprolol"}, {"id": "D000002216", "term": "Captopril"}, {"id": "C000052035", "term": "Trandolapril"}, {"id": "D000013148", "term": "Spironolactone"}, {"id": "D000004232", "term": "Diuretics"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000002316", "term": "Cardiotonic Agents"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "S-1", "relevance": "HIGH"}, {"id": "M21935", "name": "Natriuretic Peptide, Brain", "relevance": "LOW"}, {"id": "M15943", "name": "Spironolactone", "asFound": "Tape", "relevance": "HIGH"}, {"id": "M5476", "name": "Captopril", "asFound": "Endogenous", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "asFound": "G/kg", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M19924", "name": "Lisinopril", "asFound": "Amplitude", "relevance": "HIGH"}, {"id": "M11762", "name": "Metoprolol", "asFound": "Yeast", "relevance": "HIGH"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M19589", "name": "Bisoprolol", "asFound": "Young Children", "relevance": "HIGH"}, {"id": "M1823", "name": "Eplerenone", "asFound": "Salvage", "relevance": "HIGH"}, {"id": "M58172", "name": "Candesartan", "asFound": "Voice", "relevance": "HIGH"}, {"id": "M7822", "name": "Enalapril", "asFound": "Box", "relevance": "HIGH"}, {"id": "M58182", "name": "Candesartan cilexetil", "relevance": "LOW"}, {"id": "M18330", "name": "Enalaprilat", "relevance": "LOW"}, {"id": "M229780", "name": "Trandolapril", "asFound": "Chemistry", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}